 This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made materially false andor misleading statements andor failed to disclose that: 1 The Companys ENIGMA Trial for its flagship drug, AK002, was poorly designed; 2 Allakos cherrypicked timeframes and to engineer results for the ENIGMA trial; 3 Allakos used superficial endpoints in the ENIGMA Trial relative to FDA guidance; 4 Allakos misrepresented the number of adverse incidents that occurred during the ENIGMA Trial; 5 the ENIGMA Trial was not well-controlled; 6 Allakos failed to report key data from the ENIGMA Trial; and 7 as a result, defendants statements about Allakos business, operations, and prospects were materially false and misleading andor lacked a reasonable basis at all relevant times. 